ibrutinib sold brand name imbruvica among others small molecule drug inhibits bcell proliferation survival irreversibly binding protein brutons tyrosine kinase btk blocking btk inhibits bcell receptor pathway often aberrantly active b cell cancers ibrutinib therefore used treat cancers including mantle cell lymphoma chronic lymphocytic leukemia waldenströms ibrutinib also binds cterminal src kinases offtarget receptors btk inhibitor ibrutinib binds receptors inhibits kinase promoting cell differentiation growth leads many different side effects like left atrial enlargement atrial fibrillation treatment chronic lymphocytic world health organizations list essential ibrutinib indicated treatment mantle cell lymphoma mcl chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sll waldenströms macroglobulinemia wm marginal zone lymphoma mzl chronic graft versus host disease common frequency adverse effects include pneumonia upper respiratory tract infection sinusitis skin infection low neutrophil count low platelet counts headache bleeding bruising diarrhea vomiting inflammation mouth lips nausea constipation rash joint pain muscle spasms musculoskeletal pain fever common frequency adverse effects include sepsis urinary tract infection nonmelanoma skin cancer basalcell carcinoma squamous cell carcinoma low leukocyte count low lymphocyte count interstitial lung disease tumor lysis high uric acid levels dizziness blurred vision atrial fibrillation subdural hematoma nosebleeds small bruises broken blood vessels high blood pressure hives skin redness ibrutinib oral bioavailability fasting state fed state consumption grapefruit ibrutinib potent irreversible inhibitor brutons tyrosine kinase btk acrylamide group ibrutinib forms covalent bond cysteine residue btk active site leading sustained inhibition btk enzymatic activity btk important signalling molecule bcell antigen receptor bcr pathway plays role pathogenesis several bcell malignancies including mantle cell lymphoma mcl diffuse large bcell lymphoma dlbcl follicular lymphoma chronic lymphocytic leukemia cll preclinical studies shown ibrutinib effectively inhibits malignant bcell proliferation survival vivo well cell migration substrate adhesion early clinical studies activity ibrutinib described include rapid reduction lymphadenopathy accompanied transient lymphocytosis suggesting drug might direct effects cell homing migration factors tissue preclinical studies chronic lymphocytic leukemia cll cells ibrutinib reported promote apoptosis inhibit proliferation also prevent cll cells responding survival stimuli provided also leads reduction levels antiapoptotic protein malignant b treatment activated cll cells ibrutinib resulted inhibition btk tyrosine phosphorylation also effectively abrogated downstream survival pathways activated kinase including nfκb additionally ibrutinib inhibited proliferation cll cells vitro effectively blocking survival signals provided externally cll cells microenvironment including soluble factors baff tnfα fibronectin engagement stromal cell contact ibrutinib also reported reduce chronic lymphocytic leukemia cell chemotaxis towards chemokines inhibit cellular adhesion following stimulation bcell receptor additionally ibrutinib downmodulates expression target rituximabofatumumab targeting together data consistent mechanistic model whereby ibrutinib blocks bcr signaling drives cells apoptosis andor disrupts cell migration adherence protective tumour microenvironments ibrutinib created scientists celera genomics tool compound studying btk function covalently binds target ideal reagent generally considered ideal course acquiring hdacfocused program celera initial discovery program failed pharmacyclics also picked celeras small molecule btk inhibitor discovery program cash stock named tool compound drug completed phase ii trials johnson johnson pharmacyclics agreed codevelop drug jj paid pharmacyclics million upfront million pharmacyclics acquired abbvie may abbvie projected global sales billion billion approved us food drug administration fda november treatment mantle cell february fda expanded approved use ibrutinib chronic lymphocytic leukemia approved waldenströms macroglobulinemia march pharmacyclics abbvie agreed abbvie would acquire pharmacyclics deal completed march new indication ibrutinib approved united states patients chronic lymphocytic leukemia may new indication ibrutinib approved united states chronic lymphocytic leukemia cll small lymphocytic lymphoma january new indication ibrutinib approved united states treatment adults relapsedrefractory rr marginal zone lymphoma mzl require systemic therapy received least one prior august fda approved new indication ibrutinib treat graftversushost disease first drug approved fda february tablet formulation ibrutinib approved use united august ibrutinib combination rituximab approved united states treatment adults waldenströms macroglobulinemia wm rare incurable type nonhodgkins lymphoma january ibrutinib combination obinutuzumab approved treatment adults previously untreated chronic lymphocytic leukemiasmall lymphocytic lymphoma april fda expanded indication ibrutinib include combination rituximab initial treatment adults chronic lymphocytic leukemia cll small lymphocytic lymphoma approval based trial randomized multicenter openlabel actively controlled trial ibrutinib rituximab compared fludarabine cyclophosphamide rituximab fcr adult subjects years younger previously untreated cll sll requiring systemic janssen pharmaceutica pharmacyclics introduced new single dose tablet formulation flat pricing structure first half discontinued capsule formulation caused outcry perceived triple cost drug average janssen pharmaceutica pharmacyclics since reversed decision discontinue capsule formulation drug currently available capsule tablet ibrutinib added australian pharmaceutical benefits scheme generic ibrutinib added indian pharmaceutical benefits scheme httpsenwikipediaorgwikiibrutinib